PATENT CLAIM ANALYSIS

Application Number: 16006420
Application Type: Utility
Filing Date: 2018-06
Publication Date: 2018-10
Patent Classification: ["424", "186100"]

Abstract:
The present invention relates to anti-HIV antibodies. Also disclosed are related methods and compositions. HIV causes acquired immunodeficiency syndrome (AIDS), a condition in humans characterized by clinical features including wasting syndromes, central nervous system degeneration and profound immunosuppression that results in life-threatening opportunistic infections and malignancies. Since its discovery in 1981, HIV type 1 (HIV-1) has led to the death of at least 25 million people worldwide.

Claim (Index 10):
The isolated anti-HIV antibody of  claim 9 , or antigen binding portion thereof, wherein the heavy chain comprises a sequence selected from the group consisting of SEQ ID NOs: 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, and 129 and the light chain comprises a sequence selected from the group consisting of SEQ ID NOs: 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, and 130.

Metadata:
- Claim Count in Document: 1.0
- Percentile: 94.0
- Lexical Diversity: 1.2
- Patent Class: 424.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['14436608', '15379157', '15918343', '15559791', '15115547']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.786011582221375
- 35 USC 102 Novelty (BERT): 0.6342794737067875
- Combined Prediction Score: 0.7708383713699163
- Mean Citation Score: 461.318914
- Max Citation Score: 724.87335
- Similarity Product: 516.4680968340933

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test